Subscribe To
GBT / Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
GBT News
By The Motley Fool
August 8, 2022
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion. more_horizontal
By Market Watch
August 4, 2022
Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'
Shares of Global Blood Therapeutics Inc. GBT, +3.04% were up 34.4% in premarket trading on Thursday after Bloomberg reported that the company is "attr more_horizontal
By Seeking Alpha
June 21, 2022
Global Blood Therapeutics: Powerhouse Of The Future
In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth du more_horizontal
By Seeking Alpha
May 4, 2022
Global Blood Therapeutics Inc. (GBT) CEO Ted Love on Q1 2022 Results - Earnings Call Transcript
Global Blood Therapeutics, Inc. (NASDAQ:GBT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Steven Immergut – Senior more_horizontal
By Zacks Investment Research
May 4, 2022
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold cl more_horizontal
By Seeking Alpha
April 12, 2022
Global Blood Therapeutics: Hitting A Growth Inflection
Global Blood Therapeutics: Hitting A Growth Inflection more_horizontal
By Zacks Investment Research
March 25, 2022
Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Seeking Alpha
March 12, 2022
Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Global Blood Therapeutics: Changing My Strategy After Recent Earnings more_horizontal